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Abstract
Re-irradiation for recurrent gliomas has been discussed controversially in the past. This was mainly
due to only marginal palliation while being associated with a high risk for side effects using
conventional radiotherapy.
With modern high-precision radiotherapy re-irradiation has become a more wide-spread, effective
and well-tolerated treatment option. Besides external beam radiotherapy, a number of invasive
and/or intraoperative radiation techniques have been evaluated in patients with recurrent gliomas.
The present article is a review on the available methods in radiation oncology and summarizes
results with respect to outcome and side effects in comparison to clinical results after neurosurgical
resection or different chemotherapeutic approaches.
Background
"Measure a thousand times – and cut once"
This turkish proverb represents the effort that was put on
the issue of re-irradiation in patients with recurrent glio-
mas. In the past, re-irradiation was thought to be associ-
ated with a high incidence of severe treatment-related side
effects and was therefore prescribed only reluctantly. A
number of reports, however, have suggested that re-irradi-
ation may not be followed by the high incidence of side-
effects as feared [1]. Improvement in imaging techniques
as well as the establishment of high -precision radiother-
apy techniques such as stereotactic radiosurgery (SRS) or
fractionated stereotactic radiotherapy (FSRT) in the clini-
cal routine have enabled the radiation oncologist to pre-
cisely define a target volume and to describe it with with
stereotactic coordinates after targeting with stereotactic
methods (measure a thousand times) and to deliver high
local doses to this area (and cut once). Therefore, re-irradi-
ation has become a safe and effective means in controlling
recurrent gliomas.
It is known that local radiotherapeutic treatment is a main
component in the treatment of astrocytomas after primary
diagnosis. For low-grade tumors, althogh the exact time-
point of radiotherapy (RT) after primary diagnosis is dis-
cussed controversially, most patients are treated at some
point during the course of their disease [2,3]. For anaplas-
tic astrocytoma, there is a clear indication for RT after pri-
mary diagnosis following neurosurgical resection;
presently, combined radiochemotherapy is being evalu-
ated for WHO Grade III tumors (anaplastic astrocytomas,
AA). In patients with WHO grade IV astrocytomas, gliob-
lastoma multiforme (GBM), RT is considered the standard
postoperative measure, and, if the overall performance
status of the patient allows, to be conducted as combined
radiochemotherapy with temozolomide [4,5].
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Conventional RT is the standard of care radiotherapy
approach in patients with progressive gliomas, independ-
ently of histology. However, size of the treatment volume
varies, from small safety margins of 0.5 to 2 cm for low-
grade astrocytomas, to a 2–3 cm safety margin in the treat-
ment volume for anaplastic astrocytomas and high-grade
gliomas alike. The total recommended dose amounts to
54 Gy (1.8 Gy qd) for low-grade gliomas, and 60 Gy for
GBM, in a fractionation of 5 × 2 Gy/week. Therefore, the
majority of patients with recurrent gliomas have been pre-
viously exposed to high doses of RT.
Optimization of RT techniques and addition of novel
chemotherapeutic substances such as temozolomide have
helped significantly increase overall survival for patients
with gliomas. Depending on the histologic classification,
however, the time to progression may be few months to a
number of years, however, tumor progression can be
observed in the vast majority of patients. In this situation
the neuro-oncologist is faced with a difficult task: Therapy
options at the time of recurrence are often limited. Surgery
should be considered in all patients, however, gliomas are
infiltrative growing tumors and the risk for surgery-associ-
ated side effects should be weighed carefully against the
possibility and benefit of a surgical intervention [6,7].
Harsh et al. reported median overall survival times of 36
weeks for GBM and 88 weeks for AA after re-operation [8].
A study published by Ammirati et al. corroborated these
results with a median survival time of 36 weeks after re-
operation [9]. Repeat surgery may not be feasible in a
number of patients because of tumor infiltration into elo-
quent areas of the brain.
Systemic therapies such as chemotherapy have been used
widely as single agent or combined treatments, however,
often show only modest benefit [10]. Additionally, nowa-
days, a large group of patients has been exposed to CHT
during primary therapy, expecially patients with GBM,
potentially limiting the efficacy of chemotherapy or leav-
ing the patients with a decreased bone marrow reserve.
In 1999, Wong et al. published a review on outcomes and
prognostic factors of patients with recurrent gliomas
treated within phase II controlled trials; taken the results
from the 8 studies together, the progression-free survival
at 6 months was 21%, median progression-free survival
10 months, and median overall survival 30 weeks [11].
These data can be considered base-line data for compari-
son with subsequent studies in patients with recurrent gli-
omas. A major brake-through was the oral alkylating
agent temozolomide (TMZ) [12,13]. A multicenter phase
II study of the Temodal Brain Tumor Group achieved a
progression-free survival rate of 46% at 6 months; median
progression-free survival was 5.4 months, and overall sur-
vival 13.6 months [14]. Alternative dosing-schedules of
TMZ, such as the one-week-on/on-week off schedule
showed promising results in the past [15]; only recently,
results from a phase II study were released with a progres-
sion-free rate of 43% at 6 months [16]; median progres-
sion-free survival was 24 weeks, and median overall
survival 38 weeks.
RT offers a local, non-systemic treatment alternative that
should be considered at the time point of recurrence in
patients with gliomas. Some alternatives require neuro-
surgical intervention, such as interstitial brachytherapy,
being associated with the feared side-effects and risks of
surgery. Other options offer the benefit of a non-invasive
treatment, such as conventional external beam RT and
high-precision RT techniques.
In the following an overview of RT choices for recurrent
gliomas will be given, with description of the technical
background, treatment results and ideas for future treat-
ment concepts.
Conventional external beam RT
Conventional RT has been used in the past to treat
patients with recurrent gliomas. Small patient numbers
treated with a second course of RT were published, how-
ever, the main effects were seen in at least temporary pal-
liation [17-19]. It has been associated with high rates of
side effects, whereas the clinical outcome was not con-
vincing. Baumann et al. treated 34 patients with recurrent
brain tumors with an average of 30 Gy in 3 Gy single frac-
tions as re-irradiation [1]. Of this group, patients with
recurrent GBM showed survival from re-irradiation of 2.8
months only, and patients with recurrent LGG 8.5
months, respectively. Veninga et al. published results on
42 patients receiving re-irradiation for recurrent primary
brain tumors; the interval between the first and second
course of RT was at least 1 year in every patient [20]. RT
was deliverd with two opposing lateral fields or two
wedged fields in orthogonal direction, and a median re-
irradiation dose of 46 Gy (range, 4–55 Gy) in a median
fractionation of 5 × 2 Gy/week was applied. The median
survival and progression-free survival time after re-irradi-
ation were 10.9 months and 8.6 months, respectively.
Long-term severe complications were observed only in
patients receiving more than 204 Gy cumulative biologi-
cal equivalent dose (BED).
Precision radiotherapy
Over recent years conventional RT was improved and
three-dimensionally planned RT was introduced (3D-
CRT). Therefore, improved target definition using CT and
MRT, as well as using biological parameters such as PET
and SPECT, helped improve target.BMC Cancer 2007, 7:167 http://www.biomedcentral.com/1471-2407/7/167
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Stereotactic target localization methods with highest pre-
cision (high precision radiotherapy) offer optimal sparing of
surrounding normal tissue. The principle of stereotactic
RT was developed in the 1950s and 1960s, when Lars
Leksell developed the so called Gamma Knife for the Ster-
eotactic Radiosurgery (SRS) of brain tumors [21-23]. In the
1980s linear accelerators (LINAC) were also equipped for
stereotactic radiation treatments. Stereotactic irradiation
has been implemented widely in the clinical routine and
has been proven to be effective for brain metastases, men-
ingioma, acoustic neuroma and primary brain tumors
[24-26]. The required dose can be applied in a single frac-
tion as Stereotactic Radiosurgery (SRS), as or the total dose
can be applied in a number of fractions, as Fractionated
Stereotactic Radiotherapy (FSRT). Both modalities have
been used effectively for the treatment of recurrent glio-
mas.
Stereotactic radiosurgery (SRS)
SRS is a highly conformal, non-invasive, precision radio-
therapy technique. Due to its accuracy and steep dose gra-
dients at the field it is possible to deliver a prescribed dose
to a defined target volume while sparing surrounding
healthy tissue, including organs at risk [25,27,28].
Commonly, SRS is limited to smaller treatment volumes
to prevent high incidences of radiation-induced injury; it
is known that the risk of treatment-related side effects
increases with target size as well as an increase in RT dose.
Shrieve et al. observed median survival times of 10.2
months after SRS for recurrent GBM; significant prognos-
tic factors included tumor size and age [29]. At the Depart-
ment of Radiation Oncology in Heidelberg, Germany, we
treated 32 patients with recurrent glioma with SRS; a
median dose of 15 Gy was applied to a median target vol-
ume of 10 ml. During follow up, no severe treatment
related side effects could be observed, and the median sur-
vival from SRS was 10 months [27]. However, other
groups have reported higher incidences of treatment
related side effects, especially in larger target volumes. In
a study published by Hall et al., 14% of the patients devel-
oped radiation-induced necrosis, while survival calculated
from SRS was 8 months [30]. The comparably high rate of
severe side-effects might be due to the relatively larger vol-
umes (median 28 cm3) treated with SRS. However, the
higher rate of necrosis in the study published by Hall et al.
might also be due to the higher median dose of 20 Gy
applied. The University of Minnesota, Department of
Radiation Oncology published results of SRS in 46
patients with recurrent gliomas; a median dose of 17 Gy
was prescribed to a median target volume of 30 ml; 14 out
of 46 (30%) patients developed severe late complications
such as necrosis [31].
A selection of reports on SRS in recurrent gliomas can be
found in table 1. Data conclude that SRS is a safe and fea-
sible treatment alternative, however, due to the higher risk
of severe treatment-related side effects with increasing tar-
get size, SRS should be reserved for smaller lesions.
Fractionated stereotactic radiotherapy (FSRT)
FSRT is another non-invasive precision RT technique: The
required therapeutic dose is divided into a number of frac-
tions. By exploiting the radiobiological advantage of frac-
tionation, the risk of side effects to normal tissue can be
minimized. FSRT can be applied safely for very small tar-
get volumes as an alternative to SRS; moreover, for large
tumors, FSRT can also be performed safely and effectively
without the high risk of side effects associated with SRS in
such tumors.
A number of groups have studied FSRT in patiens with
recurrent gliomas (table 3). A very large series of patients
treated at the Department of Radiation Oncology at the
University of Heidelberg consisted of 172 patients treated
with FSRT for recurrent gliomas [32]. In this group,
median overall survival of 21 months, 50 months and 111
months could be observed for GBM, anaplastic astrocy-
Table 1: Series of patients with recurrent gliomas treated with stereotactc radiosurgery (SRS).
Author Pt. Number Histology Median Dose 
(Gy)
Tumor size (ml; 
median)
Median survival 
(months)
Rate of Severe 
Toxiticy/
Reoperation 
rate (%)
Chamberlain et al, 1994 20 5 GBM, 10 AA, 5 
other
13.4 17 8 -
Cho et al., 1999 46 27 GBM/19 AA 17 10 11 22%
Combs et al., 2005 32 GBM 15 10 10 -
Hall et al., 1995 35 26 GBM, 9 AA 20 28 8 31%
Kondziolka et al., 1997 23 AA 15.6 6 31 23%
Kondziolka et al., 1997 19 GBM 15 6.5 30 19%
Shrieve et al., 1995 86 GBM 13 10.1 10.2 22%BMC Cancer 2007, 7:167 http://www.biomedcentral.com/1471-2407/7/167
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toma or low-grade glioma recurrences, respectively. The
rate of severe radiation induced side effects was very low.
Other series using FSRT for recurrent gliomas are summa-
rized in table 2. Hudes and colleagues reported a median
survival of 10.5 months in a series of 20 patients treated
with FSRT, with no radiation-induced late toxicity [33].
45% of the patients improved with respect to neurological
symptoms; however, tumor volumes were comparably
small with 12.7 ml.
Hypofractionated stereotactic radiotherapy (H-FSRT)
Hypofractionated stereotactic radiotherapy (H-FSRT) is
characterized by potentially lower toxicity than SRS, how-
ever, compared to FSRT, the risk for side effects seems
increased due to the higher single doses (table 3). A major
advantage of the fewer treatment fractions is the reduction
of overall treatment time which is an especially important
issue in terminally ill patients. Shepherd et al. treated 36
patients with H-FSRT with total doses between 20 and 50
Gy, in single fractions of 5 Gy. A major predictor of radia-
tion damage was a total dose > 40 Gy; 36% of the patients
developed steroid-dependent toxicity, and 6% of the
patients required re-operation [34]. A dose escalation
study published by Hudes et al. applied doses from 24 Gy
to 35 Gy in median fractions of 3 Gy to 20 patients; no
grade 3 toxicities could be documented, and no reopera-
tion due to toxicity was required. Median survival from H-
FSRT was 10.5 months.
A recent study published by Vordermark et al. reports on
19 patients with recurrent gliomas treated with H-FSRT
[35]. The median survival from H-FSRT was 9.3 months,
with 16% survival at 2 years, and a very low rate of side-
effects. The strongest predictors for survival were total
dose (< 30 Gy vs. 30 Gy) as well as tumor histology.
For each patient, the choice, whether SRS, H-FRST or FSRT
is the appropriate treatment, has to be made individually,
depending on the size of the lesion, the location and the
previously applied RT dose and target volume. In general,
it should be considered that increasing fraction size can be
associated with an increase in treatment-related side
effects (Fig. 1). Besides lesion size, there is a response-rela-
tionship the prescribed dose and the risk for severe treat-
ment-related side effects [36]. Flickinger et al. proposed a
model to estimate complication risk for linear accelerator
radiosurgery using an integrated logistic formula [37]:
Dose-volume isoeffect curves were calculated for a 3% risk
of brain necrosis. The previous analysis of Kjellberg how-
ever, calculated a risk of 1% for a lesion with a diameter of
20 mm and a prescibed dose of 24 Gy. Additionally, with
respect to the clinical situation, it is often difficult to dis-
tinguish between tumor progression and necrosis; moreo-
ver, is must be kept in mind that, according to the initial
definition of SRS postulated by Leksell in 1951, is the aim
to induce a circumsribed necrosis. Therefore, necrosis is
per se not a complication of SRS, but a therapeutic effect.
Therefore, the crucial aspect is that no healthy tissue
should be destroyed by SRS, potentially leading to severe
clinical symptoms. Several studies report rates of necrosis
and/or reopreation rates, however, not in all cases can be
determined whether reoperation was due to tumor pro-
Table 2: Series of patients with recurrent gliomas treated with fractionated stereotactic radiotherapy (FSRT).
Author Pt. Number Histology Tumor size 
(ml; median)
Median 
Dose (Gy)
Median Fraction 
Size (Gy)
Median 
survival (months)
Rate of Severe 
Toxiticy/Reoperation 
rate (%)
Cho et al., 1999 15 (10) GBM (AA) 74 37.5 2.5 11 12%
Combs et al., 2005 71 LGG 49.3 36 2 111 -
Combs et al., 2005 42 AA 36 2 50
Combs et al., 2005 59 GBM 36 2 21
Table 3: Series of patients with recurrent gliomas treated with hypofractionated stereotactic radiotherapy (H-FSRT).
Author Pt. Number Histology Tumor size 
(ml; median)
Median 
Dose (Gy)
Median Fraction 
Size (Gy)
Median 
survival (months)
Rate of Severe 
Toxiticy/Reoperation 
rate (%)
Ernst-Stecken et al., 2006 15 GBM 22.4 35 7 - 0%
Hudes et al., 1999 19 (1) GBM (AA) 12.6 30 3 10.5 0%
Laing et al., 1993 22 GBM - 30–50 (range) 5–6 (range) - -
Selch et al., 2000 15 (3;3) GBM (AA/LGG) 12 25 4–6 (range) 6.7 0%
Shepherd et al., 1997 29 (7) GBM/AA (LGG) 24 20–50 (range) 5 11 (GBM/AA) 36%
Vordermark et al., 2005 10 (19) II or III 15 30 5 13.5 26%
Vordermark et al., 2005 9 (19) IV 15 30 5 7.4BMC Cancer 2007, 7:167 http://www.biomedcentral.com/1471-2407/7/167
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gression, or mainly due to symptomatic radiation-
induced necrosis.
Thus, for each clinical situation the choice whether SRS
should be applied, with the advantage of short treatment
times, however, with a higher risk of side effects, or
whether FSRT of H-FSRT is chosen, with a lower toxicity-
risk but with a longer treatment course, should be
weighed against each other, taking into account such fac-
tors as patients' performance status, size and location of
the lesion as well as previous therapies. H-FSRT with fewer
large fractions as compared to FSRT may shorten overall
treatment time, but may compromise too much of the
potential advantages of fractionation.
Intensity modulated radiotherapy (IMRT)
IMRT is another modern high-precision RT technique that
offers advantages for patients with complex tumor or tar-
get volumes such as skull base or paraspinal tumors, in
close vicinity to organs at risk. In such cases, better dose
conformality and sparing of normal tissue can be
achieved as compared to conventional conformal RT [38-
40]. A major down side is considered to be an increased
dose inhomogeneity within the target volume, and in
some cases, an increased low dose bath to surrounding
healthy tissue. Therefore, the use of IMRT for the irradia-
tion of gliomas cannot be considered to be superior to
FSRT, and the increased preparation time needed may not
lead to an improved patient treatment. However, a
number of groups have studied IMRT in gliomas [41-43].
Voynov et al. treated 10 patients with recurrent gliomas
with IMRT in a hypofractionated regimen [43]: In 5 Gy
single doses, median total doses of 30 Gy were delivered.
After re-irradiation with IMRT, the median survival time
was 10.1 months.
Interstitial radiotherapy
Interstitial RT using radioactive seeds as permanent or
temporary brachytherapy was performed in the 1980s in
a large number of patients using high-activity iodine-125
(125I) or iridium-192 (192I; table 4).
Implantation of 125I seeds for recurrent glioma has been
shown to offer excellent palliation in a majority of
patients and a significant level of long-term survival. 125-I
seeds can be used for permanent or for temporary
implants. In a number of cases improved survival was
seen, however, along with high rates of radionecrosis [44-
Table 4: Series of patients with recurrent gliomas treated with I-125 seed implants.
Author Pt. Number Histology (Median) Dose (Gy) Median 
survival (months)
Rate of Severe 
Toxiticy/Reoperation rate (%)
Permanent Brachytherapy
Gaspar et al., 1999 37 (22) GBM (AA) 100 10.5 44%
Halligan et al, 1996 22(4) GBM (AA) - 16 5%
Larson et al., 2004 38 GBM 150–500 12.0 10%
Patel ell., 2000 40 GBM 120–160 11.8 0%
Temporary Brachytherapy
Gutin et al., 1987 18 GBM - 13 41%
Leibel et al., 1989 45 GBM 70 12.5 49%
Leibel et al., 1989 50 AA 70 18.7
Shrieve et al., 1995 32 GBM 50 11.5 44%
Simon et al., 2002 42 GBM 40–60 12.5 24%
Sneed et al, 1997 45 AA 64 12.3 53%
Sneed et al., 1997 66 GBM 64 11.7 46%
Glia Site Temporary Brachytherapy
Chan et al., 2005 24 GBM 53 9.1 33%
Gabayan et al., 2006 80 GBM 60 Gy 8.9 2%
Gabayan et al., 2006 15 Non-GBM 60 Gy 10.9
Severe treatment-related toxicity in patients with recurrent  gliomas treated with FSRT, SRS of hypofractionated RT Figure 1
Severe treatment-related toxicity in patients with recurrent 
gliomas treated with FSRT, SRS of hypofractionated RT.BMC Cancer 2007, 7:167 http://www.biomedcentral.com/1471-2407/7/167
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47]. Seed implants can produce inhomogeneous radia-
tion dose distributions, associated with repeated opera-
tions for radionecrosis occurring in up to 64% of patients
treated with interstitial implants [47-50]. Stereotactic
placement of multiple sources around a surgical cavity is
a technically challenging procedure, most likely explain-
ing the frequently occuring area of inadequate dosing;
suboptimal dosimenty could explain the relatively poor
results observed in some trials [46,51]. The use of low-
dose-rate (LDR) interstitial brachytherapy with perma-
nent 125I implants has reduced the rate of severe compli-
cations including syptomatic radionecrosis. Permanent
LDR brachytherapy does not require stereotactic frame
placement or the drilling of multiple holes in the skull for
seed placement. However, as with high-dose-rate (HDR)-
temporary implants optimal dosimetry may be difficult to
achieve. Survival in patients with recurrent GBM treated
with this technique is comparable to that observed in sim-
ilar patients treated with brachytherapy using temporary
high-acitivity implants [52,53].
Permanent brachytherapy is performed immediately after
neurosurgical resetion, using 125I sources placed around
the surgical cavity and implanted into the surrounding
brain tissue. The total dose rate over the lifetime of the
radiation sources lies between 100 and 400 Gy, however,
the dose rate is much lower than for temporary brachy-
therapy, during which 50 to 65 Gy are applied over 4 to
12 days. For GBM, median survival times after permanent
brachytherapy range from 10.5 months to 12 months [52-
54]. Patel et al. treated 40 patients with recurrent GBM
with permanent interstitial implants, with a dose between
120 and 160 Gy; none of the patients developed severe
side effects such as radiation necorsis or injury, and sur-
vival after implantation was 47 weeks [53].
Using temporary brachytherapy, the groups of Sneed (n =
66 GBM, n = 45 AA), Shrieve (n = 32 GBM) and Chan (n
= 24 GBM) could obtain median survival times of 11.7,
11.5, 12.3 and 9.1 months, respectively [29,55,56].
Median doses between 50 and 64 Gy were applied, and
reoperation rates after treatments were betwwen 8% and
53 %. Leibel et al. reported on a series of 95 patients with
recurrent malignant gliomas treated with brachytherapy
after initial conventional RT (dose range 40–72 Gy); for a
selected group of patients, interstitial implantation of 125I
sources (dose range, 52.7 – 150 Gy) resulted in a median
survival of 18.7 and 12.5 months for anaplastic astrocyto-
mas and GBM, respectively [47]. In 49% of the patients re-
operation was required due to treatment-associated
necrosis within the high-dose area of the implantation.
Gutin et al. compared the survival of 18 patients treated
with 125I implants for recurrent GBM with 42 historical
controls treated with chemotherapy. Median survival in
the 125I-group was 52 weeks as compared to 28 weeks after
chemotherapy [57].
192Ir-wires applied through Nylon catheters placed into
the tumor recurrence under stereotactic conditions were
used for temporary brachtherapy by Simon et al. [58]. 42
patients with recurrent GBM were treated with tumor
doses between 15 and 60 Gy, over a 7 to 12 day period.
Thereafter, radioactive wires were removed at bedside and
the catheters were taken out by the neurosurgeons. Over-
all survival was 80% at 6 months, 48% at 1 year and 11%
at 2 years; 14% of the patients experienced complications
from brachytherapy, including skin necrosis.
A novel alternative temporary brachtherapy technique is
intracavitary low-dose rate (LDR) brachytherapy, also
referred to as Glia-site brachytherapy [59]. It is performed
with an expandable balloon catheter (GliaSite Radiation
Therapy System (RTS), Cytyc Surgical Products, Palo Alto,
CA, USA) which is placed into the resection cavity at the
time of tumor resection or debulking; the GliaSite system
offers balloons with 2,3 and 4 cm diameter. After a period
of 2 to 4 weeks after surgery the catheter is filled with an
aqueous solution of organically bound 125I (Iotrex
[sodium 3-(125I)-iodo-4-hydroxybenzenesulfonate]) for a
predetermined amount of time of about 3 to 6 days until
the calculated dwell time has been achieved. Thereafter,
the Iotrex is retrieved transcutaneously. The feasibility and
saftey of the system was published by Tatter et al.; the
implantation, radiation delivery as well as the expantation
were carried out without any serious side effects [59]. An
initial report on the system was published by Shrieve et al.
in 1995 [60].
The target volume for GliaSite brachytherapy is consid-
ered to be the residual enhancing tissue identified in post-
operative MRI-scans, and it is calculated to receive at least
100% of the prescribed dose. GliaSite functions as a single
spherical source of low-dose rate radiation and the pho-
ton energy of 125I (27–35 keV photons) result in rapid
attenuation over short distances via the photoelectric
effect, which leads to a steep dose fall-off and a typical pre-
scription depth of 0.5 to 2 cm.
Gabayan et al. published a retrospective analysis of 95
patients with recurrent WHO grade III and IV gliomas
treated with GliaSite [61]. The median dose applied was
60 Gy using ballon sizes between 2.0 and 4.0 cm and a
median survival time calculated from re-operation was
36.3 weeks. Little information is given on the resection
status and its impact on outcome after GliaSite brachy-
therapy; patients undergoing total or at least subtotal
resection are known to present with more favourable out-
comes, and no data is provided on the number of patients
that were treated a biopsy only. Therefore, no conclusionBMC Cancer 2007, 7:167 http://www.biomedcentral.com/1471-2407/7/167
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can be made as to which patients profit most from Glia-
Site brachytherapy.
Chan et al. treated 24 patients with Glia Site brachyther-
apy, with a rate of 8% of symptomatic necrosis and sur-
vival times of 9.1 months [56].
Intraoperative electron radiotherapy (IOERT)
IOERT is implemented in clinical routine expecially for
rectal carcinoma, sarcomas or for pancreatic carcinomas
[62,63]. Only a limited number of centers are equipped
with dedicated IOERT machines. Irradiation is performed
in the operating room, and RT is applied directly into the
resection cavity.
Few data exist on IOERT in patients with gliomas. How-
ever, the rational of local dose escalation by an electron
boost directly into the surgical cavity, especially for unre-
sectable or only partially resectable tumors, seems a
promising treatment alternative.
First promising results on IOERT were published by the
groups of Sakai and Matsutani in patients with primary
malignant brain tumors, however, could not be repro-
duced by European studies so far [64-66]. Therefore, for
primary gliomas, addition of IOERT to conventional treat-
ment (surgery and RT) has not proven to significantly
improve outcome [67,68].
However, for recurrent gliomas, a number of studies have
shown that IOERT is safe and feasible with acceptable
results without signficantly increasing sugery times. A
major downside is the "invasive" nature, i.e. IOERT can
only be performed in the neurosurgical setting.
Japanese data reported by Hara et al. on 6 patients with
recurrent gliomas showed superior results in patients
treated with surgery and IOERT than surgery alone or in
combination with chemotherapy [69]. Shibamoto et al.
evaluated the feasibility of IOERT in 19 patients with
recurrent brain tumors of different histologies [70]. RT
had been part of the initial treatment with a mean dose of
53 Gy (range, 17–65 Gy). IOERT was applied in a dose
range of 23–40 Gy. During follow up, three cases of symp-
tomatic brain necrosis occurred, one of which was fatal.
For the subgroup of patients with anaplastic astrocytomas
or GBM, median survival from IOERT was 12 months.
Ortiz de Urbina published results on IOERT in 9 patients
with recurrent gliomas; the actuarial 18 months survival
rate and survival time was 47% and 13 months in this
group. The median time to tumor progresseion after
IOERT was 11 months. IOERT was applied in single doses
of 10–20 Gy, and no IOERT related mortality was
observed [71].
At the University Hospital of Muenster in Germany IORT
has been performed since 1992 for gliomas. In total 71
patients were treated, of which 19 were treated for recur-
rent gliomas [67]. In these patients, electron-beam IORT
was performed with 15–25 Gy, depending on size of the
lesion, doses and field location of previously performed
RT as well as the RT dose applied prior to IORT. Disease-
free survival in this subgroup was 12.45 months. Periop-
erative complications were not increased in the IORT-
group, however, no clear statement could be made on the
incidence of severe side-effects such as brain necrosis.
Radio-chemotherapy
To further optimize treatment results obtained by re-irra-
diation, chemotherapy might be added to RT. However,
this combined approach is likely to increase side effects,
especially in substances with strong radiosensitizing
potential. As re-irradiation alone is applied with caution,
radio-chemotherapy as re-irradiation is performed even
more restricted.
Only few groups have studied combined re-iradiation and
chemotherapy in recurrent gliomas (table 5).
Wurm et al. combined HFSRT with topotecan chemother-
apy in 25 patients; histology was AA in 20% and GBM in
80%, respectively. RT was applied in a median dose of 30
Gy in 5–6 fractions [72]. Overall survival was 14.5
months, 12% of the patients developed adverse RT-
induces side effects. Topotecan was prescribed in a dose of
1.1 mg/m2 qd as continuous infusion during H-FSRT fol-
lowed by up to 48 courses of chemotherapy.
Table 5: Series of patients with recurrent gliomas treated with radio-chemotherapy.
Author RT-Technique Chemotherapy Pt. 
Number
Histology Tumor size 
(ml; median)
Median 
Dose (Gy)
Median Fraction 
Size (Gy)
Median survival 
(months)
Rate of Severe 
Toxiticy/
Reoperation 
rate (%)
Arcicasa et al., 1999 CH-EBRT CCNU 24 (7) GBM (AA) - 34.5 1.5 13.7 -
Glass et al., 1997 CH-HSFRT Cisplatin 13 (7) GBM (AA) 14 35–42 (range) 3.5–6 (range) 13.7 -
Lederman et al., 2000 CH-HSFRT Paclitaxel 88 GBM 32.7 18–36 (range) 4–9 (range) 7 11%
Wurm et al., 2006 CH-HSFRT Topotecan 5 (25) III 16.5 30 5 21.3 -
Wurm et al., 2006 CH-HSFRT Topotecan 20 (25) IV 16.5 30 5 7.9BMC Cancer 2007, 7:167 http://www.biomedcentral.com/1471-2407/7/167
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Glass et al. combined HFSRT with cisplatin weekly (40
mg/m2) in 20 patients with recurrent AA and GBM [73]. A
median survival of 12.7 months was observed, with a rate
of 15% of necrosis at re-operation. Another group com-
bined HFSRT with paclitaxel weekly (120 g/m2) in 88
patients with GBM; median overall survival was 7 months
[74]. Only 8% presented with necrosis at re-operation.
Thirty-one patients with recurrent GBM and AA were
treated with re-irradiation and lomustine (CCNU) at the
Department of Radiation Oncology in Aviano, Italy [75].
Oral administration was begun concomitantly with re-
irradiation and was repeated every 6 weeks. Toxicity was
moderate, however, also treatment results were observed
with only modest subjective and objective response rates;
on the other hand, survival from relapse was remarkable
at 13.7 months.
Chamberlain et al. combined 125I-brachytherapy with
concurrent cisplatin; in 16 patients stereotactically placed
catheters were afterloaded with 125I sources with a median
50 Gy minimum treatment volume dose during a 100
hour period along with cisplatin 20 mg/m2 qd over 5 days.
Early complications included headache, seizures and
worsening of neurological symptoms; late complications
included radiation-induced necrosis in 9 patients requir-
ing reoperation [76]. A partial response was seen in 5
patients, stable disease in 7 and progressive disease in 3
patients over a median follow-up time of 9.5 months.
Hyperthermia
It is known that an increase in temperature to a certain
level enhances the anti-tumor action of chemotherapy
and radiotherapy, alike [77,78]. For therapeutic hyper-
thermia, temperatures between 44°C – 46°C are consid-
ered to be effective. Above this temperature, coagulation
necrosis occurs, which is a principle used in thermo- or
radio-frequency-ablation. In oncological concepts, the
direct cytotoxic effect of hyperthermia is anticipated, but
also the chemo- and radiation-sensitizing effect of higher
temperature.
Therefore, there was hope that hyperthermia might help
improve outcome in patients with gliomas. Sneed et al.
recruited 112 patients within 5 years with tumor manifes-
tations not exceeding 5 cm in diameter [79]. Within this
two armed study, patients in both arms were treated with
brachtherapy; in one arm, 30 min prior to brachtherapy
hyperthermia was applied. Progression-free survival could
be increased from 33 to 49 weeks in the group treated
with hyperthermia, and overall survival could be extended
9 weeks by application of hyperthermia; 2-year survival
rates were 0% and 10% for the two groups, respectively.
However, technical setup and treatment procedures were
complex.
Proton radiotherapy/Carbon ion radiotherapy
Particle therapy such as proton and carbon ion treatment
has been implemented for patient treatment over the last
years. In certain tumor entities carbon ion RT has been
shown to offer significantly better tumor control as com-
pared to photon RT [80,81]. Protons and carbon ions as
well are characterized by a distinct physical so called
inverse dose profile; this results in a high dose deposition
very locally in the so-called Bragg Peak, and a steep dose
fall-off thereafter. Additionally, carbon ion beams offer an
increased relative biological effectiveness (RBE) which is
known to be especially beneficial in radioresistant,
hypoxic and/or slow-growing tumors.
Worldwide, a number of centers offer particle beams; at
the University of Heidelberg, carbon ion radiotherapy is
performed at the Gesellschaft für Schwerionenforschung
(GSI) in Darmstadt. In 2007, the Heidelberg Ion Therapy
Center will take up patient treatment offering proton and
carbon ion RT. Preliminary data from Japan have shown
effectivity of C12 in patients with GBM, however, in this
series, no concomitant chemotherapy was applied which
is considered the standard for the treatment of primary
GBM [82]. Since further investigation of C12 in patients
with gliomas is warranted, implementation of C12  to
recurrent astrocytomas will be evaluated in a clinical set-
ting at the Department of Radiation Oncology in Heidel-
berg, Germany, in the near future.
Conclusion
In the past, a number of attempts have been made to sal-
vage patients with recurrent gliomas with a second course
of radiotherapy. A number of invasive and non-invasive
techniques are available and have proven effectivity in
recurrent gliomas. Certainly, every patient confronts us
with an individual setting, including tumor size, location,
previous treatments as well as performance status and
clinical symptoms. The choice as to which modality
should be applied has to be made individually for each
patient, reflecting possibilities, potential benefit and side-
effects.
For all RT modalities, close vicinity to sensitive risk struc-
tures is a main obstacle for a second course of RT since the
risk for severe side effects, confining quality of life or jeop-
ardizing even vital organ functions, are high due to the
limited tolerance dose [83]. Especially for SRS as well as
invasive procedures such as brachytherapy, the potential
toxicity becomes of major concern if the tumor becomes
larger or is located close to eloquent structures, such as the
optic pathway, basal ganglia, motor or speech areas or the
brain stem.
Using modern highly conformal RT techniques, precise
dose application to a defined target volume is possibleBMC Cancer 2007, 7:167 http://www.biomedcentral.com/1471-2407/7/167
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while the surrounding normal tissue can be spared, in a
non-invase approach. Therefore, treatment related toxicity
can be minimized, while treatment results can be
improved. Re-irradiation using high precision radiother-
apy offers significant benefit, at least for a subgroup of
patients. For each patient, the fractionation scheme must
be chosen individually.
However, it is not a curative treatment and further
improvement is needed urgently. Further investigation of
combined radiochemotherapy as well as novel RT modal-
ities such as carbon ion RT are needed.
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